Business Description

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS We were founded in 1993, reincorporated in Delaware in 2007, changed our name to AdvanSource Biomaterials Corporation in 2008 and changed our name to EKIMAS Corporation in 2020. On October 12, 2021, we entered into a Stock Purchase Agreement (the “SPA”) with Reddington Partners LLC, a California limited liability company (“Reddington”), providing for Reddington’s purchase of a total of 511,448 shares of our common stock, on a post-split basis, or approximately 90 % of our total outstanding common stock, for total cash consideration of $ 400,000 . Reddington purchased the common stock in two tranches, which closed on October 12, 2021 (the “First Closing”) and March 15, 2022. Pursuant to the SPA, the Company effected a 1-for-50 reverse stock split on March 11, 2022 (the “Reverse Split”). On a post-split basis, Reddington acquired 42,273 at the First Closing and an additional 469,175 shares at the March 15, 2022 second closing, after which Reddington owned 511,448 shares of our common stock, or approximately 90 % of our total outstanding common stock. On February 23, 2023, the Company acquired NP Bioinnovation A/S (formerly Nordicus Partners A/S and Managementselskabet af 12.08.2020 A/S), a Danish stock corporation, pursuant to a contribution agreement with NP Bioinnovation A/S, GK Partners ApS, Henrik Rouf and Life Science Power House ApS. The sellers contributed 100 % of the issued and outstanding capital stock of NP Bioinnovation A/S to the Company in exchange for an aggregate of 250,000 shares of the Company’s common stock, and NP Bioinnovation A/S became a wholly owned subsidiary of the Company. On February 23, 2023, Tom Glaesner Larsen and Christian Hill-Madsen were appointed directors of the Company. On May 17, 2023, the Company changed its name to Nordicus Partners Corporation and its ticker symbol to NORD. On June 1, 2023, the Company acquired a 4.99 % interest in Mag Mile Capital, Inc., a commercial real estate mortgage banking firm headquartered in Chicago. On June 9, 2023, Mr. Tom Glaesner Larsen resigned as a director of the Company and Henrik Keller was appointed as his replacement. On November 29, 2023, the Company’s subsidiary, Nordicus Partners A/S, changed its name to Managementselskabet af 12.08.2020 A/S. Subsequently on March 10, 2025, Managementselskabet af 12.08.2020 A/S changed its name to NP Bioinnovation A/S. On May 13, 2024, the Company acquired a 95 % interest in Orocidin A/S (“Orocidin”), a Danish preclinical-stage biotechnology company advancing next-generation periodontitis therapies, in exchange for 3,800,000 restricted shares of the Company’s common stock. On June 3, 2024, Mr. Christian Hill-Madsen resigned as a director of the Company and Peter Severin was appointed as his replacement. On November 8, 2024, the Company effected a 1-for-10 reverse stock split of its issued and outstanding common stock, rounding up for fractional shares. The reverse stock split had no effect on the Company’s authorized shares of common stock or preferred stock, and the par value of each class remained $ 0.001 . All common stock share, option, warrant and per-share amounts, except authorized but unissued shares, have been retroactively adjusted in these consolidated financial statements and related disclosures. On November 11, 2024, the Company announced that it had entered into an agreement to acquire 100 % of the outstanding shares of Bio-Convert A/S (“Bio-Convert”), a Denmark-based preclinical-stage biotechnology company developing treatments for oral leukoplakia, in exchange for 12,000,000 restricted shares of the Company’s common stock. On November 12, 2024, the Company acquired the remaining 29,663 outstanding shares, or approximately 5 %, of Orocidin A/S in exchange for 200,000 restricted shares of the Company’s common stock, after which Orocidin A/S became a wholly owned subsidiary of the Company. On August 7, 2025, (1) Henrik Keller resigned from the Board of Directors of the Company, (2) the Board increased its size from three to five members and (3) Torben S. Jensen, Kim T. Mücke and Andrew J. Ritter were appointed to fill the resulting vacancies. The Company executed a director agreement with each of Messrs. Jensen, Mücke and Ritter, under which each will receive an annual cash retainer of $ 10,000 , payable in two installments per calendar year in accordance with the Company’s standard compensation plan for Board members. Messrs.…